Carrier testing analyses DNA from adults to identify whether an individual carries a recessive allele for a genetic disorder. It is most commonly used when there is a relevant family history or before starting a pregnancy.
Preimplantation Genetic Diagnosis (PGD) evaluates early embryos produced during IVF. A few embryonic cells are removed for genetic analysis, and only embryos free of specific harmful alleles are considered for implantation.
Prenatal testing uses DNA obtained from the developing fetus, typically via chorionic villus sampling (CVS) or amniocentesis. These tests diagnose genetic conditions while the pregnancy is ongoing.
Cell sampling and analysis rely on extracting fetal or embryonic cells and using molecular assays such as PCR or targeted sequencing to detect specific genetic variations with high precision.
| Feature | Carrier Testing | PGD | Prenatal Testing |
|---|---|---|---|
| Sample source | Adult somatic cells | Embryo cells | Placental or amniotic cells |
| Timing | Before pregnancy | During IVF | During pregnancy |
| Risk level | No physical risk | Minimal risk | Small risk of miscarriage |
| Decision outcome | Family planning | Embryo selection | Pregnancy continuation or intervention |
Risk differences influence which method is appropriate; PGD avoids miscarriage risks associated with prenatal testing, while prenatal testing provides information after natural conception.
Ethical considerations vary, as PGD involves selecting embryos before implantation, while prenatal testing may influence decisions during pregnancy.
Identify the test purpose clearly, since exam questions often ask whether the scenario calls for carrier testing, PGD, or prenatal testing. Focus on whether the context involves adults, embryos, or fetuses.
Check timing clues, such as whether fertilisation has occurred naturally or via IVF. These details determine whether PGD or prenatal testing is applicable.
Evaluate risk information, particularly miscarriage risks and timing within pregnancy, to support written explanations or comparisons in structured questions.
Explain ethical considerations with balanced reasoning, presenting multiple viewpoints rather than only one moral or cultural perspective.
Confusing screening with diagnosis is common; screening assesses risk or presence of alleles, while diagnosis confirms a condition. Exams often expect this distinction explicitly.
Misinterpreting carrier results can lead to incorrect predictions; a carrier does not have the disorder but can pass on a recessive allele, which is central to risk assessment scenarios.
Assuming all prenatal tests are equal overlooks key differences such as timing, risk, and the ability to detect certain disorders, which are frequently tested in comparison questions.
Overlooking the limitations of tests, such as false positives or false negatives, leads to incomplete answers when discussing ethical or practical implications.
Genetic counselling integrates screening results with medical, ethical, and psychological support. This interdisciplinary connection is essential for understanding the real-world use of screening.
Population genetics benefits from screening data, which can reveal carrier frequencies and guide public health strategies for managing inherited disorders.
Advances in sequencing technology continue to expand the scope of screening, allowing whole-genome or exome analysis to identify previously undetectable variants.
Ethical frameworks in bioethics help society navigate complex issues surrounding embryo selection, informed consent, and reproductive autonomy.
